CompletedNot Applicable

Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab

Russia15 participantsStarted 2023-12-19

Plain-language summary

In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pediatric patients with Neterton syndrome * Treatment with secukinumab and/or dupilumab for at least 3 months Exclusion Criteria: * Irregular administration of therapy * Development of a serious adverse event

What they're measuring

overal survival Kaplan-Mayer method

Timeframe: 3 and 6 months from the start of each type of therapy

Trial details

NCT IDNCT07151508

SponsorFederal Research Institute of Pediatric Hematology, Oncology and Immunology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-25

View on ClinicalTrials.gov More Neterton Syndrome trials